A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

@article{Dargie2007ARP,
  title={A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.},
  author={Henry J. Dargie and Per Rossen Hildebrandt and Guenter A. J. Riegger and John J V McMurray and Stephen O McMorn and Jeremy N Roberts and Andrew Zambanini and John P H Wilding},
  journal={Journal of the American College of Cardiology},
  year={2007},
  volume={49 16},
  pages={1696-704}
}
OBJECTIVES This study investigated the effects of rosiglitazone (RSG) on left ventricular ejection fraction (LVEF) in subjects with type 2 diabetes (T2DM) and pre-existing chronic heart failure (CHF) (New York Heart Association [NYHA] functional class I to II). BACKGROUND Fluid retention is an important consideration in the use of thiazolidinediones in T2DM patients because it could exacerbate symptoms or precipitate decompensation in those with previously stable CHF. METHODS A total of 224… CONTINUE READING